Want to see JP:7792 full AI Analyst Report?
7792 Stock Chart & Stats
¥1473.00
-¥1.00(-0.09%)
At close: 4:00 PM EST
¥1473.00
-¥1.00(-0.09%)
Day’s Range― - ―
52-Week Range¥1,350.00 - ¥1,596.00
Previous CloseN/A
Volume12.30K
Average Volume (3M)17.98K
Market Cap
¥13.60B
Enterprise Value¥11.26K
Total Cash (Recent Filing)¥2.11B
Total Debt (Recent Filing)¥8.05M
Price to Earnings (P/E)9.6
Beta0.58
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.82%
Share Statistics
EPS (TTM)148.99
Shares Outstanding9,112,900
10 Day Avg. Volume25,690
30 Day Avg. Volume17,980
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)2.55
Price to Sales (P/S)1.91
P/FCF Ratio18.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Profit MarginsSustained high gross (67.33%) and net (19.20%) margins indicate durable pricing power and an efficient cost structure in the medical-devices business. These margins create long-term cash flow cushion, support reinvestment in R&D, and give flexibility to sustain profits through industry cycles.
Very Low Leverage And Strong ROEExtremely low leverage and a high equity base reduce financial risk and interest burden, while a 25.7% ROE shows efficient capital use. This balance-sheet strength supports durable investment capacity, resilience in downturns, and the ability to pursue organic growth or selective M&A without financing stress.
Healthy Cash GenerationStrong operating cash conversion and high free-cash-flow relative to net income demonstrate the business reliably converts profit into cash. Over the medium term this underpins capital expenditures, dividend capacity and deleveraging optionality, supporting sustainable operations and shareholder returns.
Bears Say
Free Cash Flow VolatilityHistorical volatility in free cash flow undermines predictability for funding capex, R&D and shareholder returns. Even with strong conversion ratios on average, intermittent FCF declines can force management to curtail investments or dividends, limiting strategic flexibility over the medium term.
Small Scale And Low LiquidityA compact workforce and low average trading volume suggest limited operating scale and market presence versus larger device peers. This constrains R&D breadth, bargaining power with suppliers/customers, and can raise per-unit costs, while limited liquidity increases execution risk for large capital moves.
Limited Investor Guidance And DisclosureAbsence of earnings guidance and limited reported call highlights reduces transparency into management's near-term plans and strategy execution. Over months this can hinder investor visibility into resource allocation and growth initiatives, complicating assessment of sustained operational progress.
Colan Totte.Co.,Ltd. News
7792 FAQ
What was Colan Totte.Co.,Ltd.’s price range in the past 12 months?
Colan Totte.Co.,Ltd. lowest stock price was ¥1350.00 and its highest was ¥1596.00 in the past 12 months.
What is Colan Totte.Co.,Ltd.’s market cap?
Colan Totte.Co.,Ltd.’s market cap is ¥13.60B.
When is Colan Totte.Co.,Ltd.’s upcoming earnings report date?
Colan Totte.Co.,Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 68 days.
How were Colan Totte.Co.,Ltd.’s earnings last quarter?
Colan Totte.Co.,Ltd. released its earnings results on Aug 07, 2026. The company reported ¥44.29 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Colan Totte.Co.,Ltd. overvalued?
According to Wall Street analysts Colan Totte.Co.,Ltd.’s price is currently Overvalued.
Does Colan Totte.Co.,Ltd. pay dividends?
Colan Totte.Co.,Ltd. pays a Notavailable dividend of ¥50 which represents an annual dividend yield of 2.82%. See more information on Colan Totte.Co.,Ltd. dividends here
What is Colan Totte.Co.,Ltd.’s EPS estimate?
Colan Totte.Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Colan Totte.Co.,Ltd. have?
Colan Totte.Co.,Ltd. has 9,112,900 shares outstanding.
What happened to Colan Totte.Co.,Ltd.’s price movement after its last earnings report?
Colan Totte.Co.,Ltd. reported an EPS of ¥44.29 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.922%.
Which hedge fund is a major shareholder of Colan Totte.Co.,Ltd.?
Currently, no hedge funds are holding shares in JP:7792
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Colan Totte.Co.,Ltd.
Colan Totte Co., Ltd., established in Osaka, Japan, in 1997, operates as an international firm specializing in the development and global distribution of therapeutic devices under its proprietary Colantotte brand. The company's diverse product portfolio features an array of magnetic therapy items for domestic use, including specialized necklaces designed to alleviate neck and shoulder discomfort, loop-style products for arm support, various general joint supporters, performance-enhancing recovery apparel, and magnetic pillows. In addition to these physical goods, they also offer sleep-enhancing supplements. Furthermore, Colan Totte manages the Colantotte Safety System, an emergency notification service accessible via a unique card, pendant, or keychain. Their sales strategy incorporates wholesale partnerships, directly managed retail outlets, and a comprehensive online platform.
Technical Analysis
PHC Holdings Corp.
―
Eiken Chemical Co., Ltd.
―
Create Medic Co., Ltd.
―
Nihon Kohden Corporation
―
Japan Medical Dynamic Marketing, Inc.
―